Vivek Subbiah: Delighted to meet with the rising young oncology star from Brazil, Juliana Beal!
Vivek Subbiah shared a post on his X/Twitter page:
“Such a delight to meet with the rising young oncology star from Brazil, Juliana Beal! She was live tweeting the Tumor Agnostic session at The San Antonio Breast Cancer Symposium (SABCS).
She is the co-first author of the paper in Trends in Cancer journal on “Impact of tissue-agnostic approvals for patients with sarcoma: Trends in Cancer” with Roberto Pestana. Link here.”
Juliana Beal, Medical oncologist at The Israelita Albert Einstein Hospital, replied saying:
“Also today marks 1 year since our paper was published! How auspicious.”
Source: Vivek Subbiah/X and Juliana Beal/X
Vivek Subbiah is the Chief of Early-Phase Drug Development at the Sarah Cannon Research Institute (USA). He is the former Executive Director of Oncology Research at the MD Anderson Cancer Network and a former Associate Professor in the Department of Investigational Cancer Therapeutics at The University of Texas MD Anderson Cancer Center. Dr. Vivek Subbiah has served as the principal investigator in over 100 phase I/II trials and co-investigator in over 200 clinical trials and is known for his leadership in several first-in-human and practice-changing studies that directly led to approvals from the FDA, European Medicines Agency, and other agencies across the world. He is an expert in tumor agnostic precision oncology and leads the BRAF and RET tissue agnostic studies to FDA approval.
-
ESMO 2024 Congress
September 13-17, 2024
-
ASCO Annual Meeting
May 30 - June 4, 2024
-
Yvonne Award 2024
May 31, 2024
-
OncoThon 2024, Online
Feb. 15, 2024
-
Global Summit on War & Cancer 2023, Online
Dec. 14-16, 2023